PE20000334A1 - Compuestos para el tratamiento de la isquemia - Google Patents
Compuestos para el tratamiento de la isquemiaInfo
- Publication number
- PE20000334A1 PE20000334A1 PE1999000156A PE00015699A PE20000334A1 PE 20000334 A1 PE20000334 A1 PE 20000334A1 PE 1999000156 A PE1999000156 A PE 1999000156A PE 00015699 A PE00015699 A PE 00015699A PE 20000334 A1 PE20000334 A1 PE 20000334A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- optionally replaced
- member ring
- inhibitor
- guanidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I; Z ES UN ANILLO DIINSATURADO DIAZA DE 5 MIEMBROS OPCIONALMENTE SUSTITUIDO CON R1, R2 Y R3 O CON R4 Y R5; R1, R2, R3, R4, Y R5 SON H, (HIDROXI)ALQUILO C1-C4, ALQUILO C1-C4, ALQUILTIO C1-C4, CICLOALQUILO C3-C4, CICLOALQUILO C3-C7, M-ALQUILO C1-C4, ENTRE OTROS; M ES UN ANILLO DE 5-8 MIEMBROS CON 1-3 N, O, S; ANILLO BICICLICO DE 3 A 6 MIEMBROS CADA ANILLO OPCIONALMENTE SUSTITUIDO POR R6, R7 Y R8; UNO DE R6, R7 Y R8 ES UN ANILLO DE 3-7 MIEMBROS CON 1-3 O, S, N OPCIONALMENTE SUSTITUIDO; R6, R7, R8 ES OH, NITRO, HALOGENO, ALCOXI C1-C4, ENTRE OTROS. SON COMPUESTOS PREFERIDOS [1-(2-CLOROFENIL)-5-METIL-1H-PIRAZOL-4-CARBONIL]GUANIDINA, [5-METIL-1-(QUINOLIN-6-IL)-1H-PIRAZOL-4-CARBONIL]GUANIDINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS UN INHIBIDOR DE ALDOSA REDUCTASA O UN INHIBIDOR DE LA GLUCOGENO FOSFORILASA O UN AGENTE FOSFORILASA O UN AGENTE CARDIOVASCULAR. EL COMPUESTO I ES UN INHIBIDOR DEL INTERCAMBIO DE SODIO-HIDROGENO DE TIPO 1 (NHE-1) Y PUEDE SER UTIL PARA EL TRATAMIENTO DE ISQUEMIA, LESION ISQUEMICA MIOCARDICA PERIOPERATORIA, Y PARA LA REDUCCION DEL DANO EN EL TEJIDO TAL COMO TEJIDO CARDIACO, CEREBRO, HIGADO, RINON, PULMON, INTESTINO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7636298P | 1998-02-27 | 1998-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000334A1 true PE20000334A1 (es) | 2000-05-13 |
Family
ID=22131525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000156A PE20000334A1 (es) | 1998-02-27 | 1999-02-23 | Compuestos para el tratamiento de la isquemia |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US6492401B1 (es) |
| EP (2) | EP1454902A1 (es) |
| JP (2) | JP2002504546A (es) |
| KR (4) | KR100407903B1 (es) |
| CN (1) | CN1289326A (es) |
| AP (1) | AP9901478A0 (es) |
| AR (1) | AR015526A1 (es) |
| AT (1) | ATE286034T1 (es) |
| AU (1) | AU739403B2 (es) |
| BG (1) | BG104803A (es) |
| BR (1) | BR9908332A (es) |
| CA (1) | CA2321642A1 (es) |
| CO (1) | CO4980897A1 (es) |
| DE (1) | DE69922930T2 (es) |
| DK (1) | DK1056729T3 (es) |
| DZ (1) | DZ2729A1 (es) |
| EA (1) | EA003603B1 (es) |
| ES (1) | ES2237080T3 (es) |
| GT (1) | GT199900022A (es) |
| HR (2) | HRP20000550A2 (es) |
| HU (1) | HUP0204418A3 (es) |
| ID (1) | ID25505A (es) |
| IL (1) | IL136588A0 (es) |
| IS (1) | IS5548A (es) |
| NO (1) | NO20004192D0 (es) |
| NZ (1) | NZ504769A (es) |
| OA (1) | OA11450A (es) |
| PA (1) | PA8468401A1 (es) |
| PE (1) | PE20000334A1 (es) |
| PL (1) | PL342444A1 (es) |
| PT (1) | PT1056729E (es) |
| SI (1) | SI1056729T1 (es) |
| SK (1) | SK12342000A3 (es) |
| TN (1) | TNSN99028A1 (es) |
| TR (1) | TR200002480T2 (es) |
| TW (1) | TWI226329B (es) |
| WO (1) | WO1999043663A1 (es) |
| YU (1) | YU46200A (es) |
| ZA (1) | ZA991578B (es) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100407903B1 (ko) * | 1998-02-27 | 2003-12-01 | 화이자 프로덕츠 인크. | 허혈 치료용 ｎ-[(치환된 5원 트리아자 이불포화고리)카르보닐] 구아니딘 유도체 |
| FR2795726A1 (fr) * | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| UA72002C2 (en) * | 1999-10-29 | 2005-01-17 | Pfizer Prod Inc | Inhibitors crystals of sodium-hydrogen exchange of 1 type, a method for the preparation thereof (variants), a pharmaceuticalcomposition based thereon and a method for the reduction of tissue damage |
| US6441176B1 (en) * | 1999-10-29 | 2002-08-27 | Pfizer Inc. | Method for preparing sodium-hydrogen exchanger type 1 inhibitor |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| US6570013B2 (en) | 2000-02-16 | 2003-05-27 | Pfizer Inc | Salts of zopolrestat |
| US6555569B2 (en) * | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| CA2398446A1 (en) | 2000-04-18 | 2001-10-25 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinases |
| OA12256A (en) * | 2000-04-28 | 2003-11-06 | Pfizer Prod Inc | Sodium-hydrogen exchanger type 1 inhibitor (NHE-1). |
| US6852733B2 (en) * | 2000-04-28 | 2005-02-08 | Pfizer Inc. | Sodium-hydrogen exchanger type 1 inhibitor |
| IL144507A0 (en) * | 2000-07-31 | 2002-05-23 | Pfizer Prod Inc | Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| MXPA03004783A (es) * | 2000-11-28 | 2003-09-10 | Pfizer Prod Inc | Preparacion de inhibidores del intercambiador de sodio-huidrogeno de tipo 1. |
| IL147696A0 (en) * | 2001-01-25 | 2002-08-14 | Pfizer Prod Inc | Combination therapy |
| US6423705B1 (en) | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
| YU51903A (sh) * | 2001-01-31 | 2006-05-25 | Pfizer Products Inc. | Enolati inhibitora izmene natrijum-vodonik tipa-1 |
| WO2002098429A1 (en) * | 2001-06-07 | 2002-12-12 | Pfizer Products Inc. | Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat |
| US7358267B2 (en) * | 2001-06-29 | 2008-04-15 | Amgen Inc. | Bis-aryl thiazole derivatives |
| PL369074A1 (en) * | 2001-11-02 | 2005-04-18 | Aventis Pharmaceuticals Inc. | Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor |
| WO2003051845A1 (en) | 2001-12-19 | 2003-06-26 | Pfizer Products Inc. | Methods for preparing sodium-hydrogen exchanger type-1 inhibitors |
| BR0307195A (pt) * | 2002-01-30 | 2004-11-03 | Pfizer Prod Inc | Composições farmacêuticas de mesilato de zoniporide e processos para melhorar a solubilidade do zoniporide |
| CA2483927A1 (en) * | 2002-05-02 | 2003-11-13 | Pfizer Products Inc. | Treatment of diabetes and diabetic complications with nhe-1 inhibitors |
| US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| FR2840302B1 (fr) * | 2002-06-03 | 2004-07-16 | Aventis Pharma Sa | Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| FR2842525B1 (fr) | 2002-07-16 | 2005-05-13 | Aventis Pharma Sa | Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant |
| FR2842526B1 (fr) * | 2002-07-16 | 2007-07-13 | Aventis Pharma Sa | Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments |
| FR2842524B1 (fr) * | 2002-07-16 | 2005-04-22 | Aventis Pharma Sa | Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments |
| EP1590338B1 (en) | 2002-12-04 | 2009-08-26 | Ore Pharmaceuticals Inc. | Modulators of melanocortin receptor |
| CN100436445C (zh) * | 2003-02-07 | 2008-11-26 | 第一制药株式会社 | 吡唑衍生物 |
| US7317109B2 (en) | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US7576121B2 (en) | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| WO2005047297A1 (en) | 2003-11-12 | 2005-05-26 | Phenomix Corporation | Heterocyclic boronic acid compounds |
| TW200526641A (en) * | 2003-12-26 | 2005-08-16 | Daiichi Seiyaku Co | Amidopyrazole derivatives |
| WO2005079803A1 (en) * | 2004-02-13 | 2005-09-01 | Pfizer Products, Inc. | Compounds for treatment of cardiovascular diseases |
| US7786163B2 (en) | 2004-07-12 | 2010-08-31 | Forest Laboratories Holdings Limited (BM) | Constrained cyano compounds |
| WO2006053274A2 (en) | 2004-11-15 | 2006-05-18 | Bristol-Myers Squibb Company | 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7226942B2 (en) | 2004-11-15 | 2007-06-05 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| WO2006055463A2 (en) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7223786B2 (en) | 2004-11-15 | 2007-05-29 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
| SI1853296T1 (sl) * | 2005-01-10 | 2012-10-30 | Debiopharm Sa | Uporaba cikličnega undekapeptida za pripravo zdravila za dajanje med miokardnimi ishemičnimi dogodki |
| WO2006113261A2 (en) | 2005-04-14 | 2006-10-26 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
| US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| WO2008005910A2 (en) | 2006-07-06 | 2008-01-10 | Bristol-Myers Squibb Company | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| CN101687873A (zh) | 2007-04-17 | 2010-03-31 | 百时美施贵宝公司 | 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂 |
| EP2173717B9 (en) | 2007-07-27 | 2013-06-26 | Bristol-Myers Squibb Company | Novel glucokinase activators and methods of using same |
| CA2722772C (en) * | 2008-04-28 | 2020-12-22 | Janssen Pharmaceutica N.V. | Benzoimidazoles as prolyl hydroxylase inhibitors |
| US10517839B2 (en) | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
| BRPI0921097B8 (pt) * | 2008-11-21 | 2021-05-25 | Raqualia Pharma Inc | composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto |
| WO2010094090A2 (en) * | 2009-02-18 | 2010-08-26 | Katholleke Universiteit Leuven | Synucleinopathies |
| JP2013523894A (ja) | 2010-04-14 | 2013-06-17 | ブリストル−マイヤーズ スクイブ カンパニー | 新規グルコキナーゼアクチベーターおよびその使用方法 |
| CN102408385B (zh) * | 2011-06-20 | 2014-06-18 | 雅本化学股份有限公司 | 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法 |
| CN102408386B (zh) * | 2011-07-27 | 2014-05-07 | 雅本化学股份有限公司 | 2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法 |
| AR087971A1 (es) | 2011-09-23 | 2014-04-30 | Bayer Ip Gmbh | Uso de derivados del acido 1-fenil-pirazol-3-carboxilico 4-sustituidos como principios activos contra estres abiotico de plantas |
| ES2689481T3 (es) | 2011-10-25 | 2018-11-14 | Janssen Pharmaceutica Nv | Formulaciones de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico |
| WO2013130411A1 (en) * | 2012-02-27 | 2013-09-06 | Essentialis, Inc. | Salts of potassium atp channel openers and uses thereof |
| US10759781B2 (en) | 2015-08-06 | 2020-09-01 | Ube Industries, Ltd. | Substituted guanidine derivatives |
| JPWO2017057695A1 (ja) * | 2015-09-30 | 2018-07-19 | 東レ株式会社 | ジフェニルピラゾール誘導体及びその医薬用途 |
| EP3395801B1 (en) | 2015-12-16 | 2021-03-31 | Nippon Soda Co., Ltd. | Arylazole compound and pest control agent |
| WO2018058109A1 (en) | 2016-09-26 | 2018-03-29 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
| CN108017584B (zh) * | 2017-06-20 | 2021-03-23 | 南开大学 | A3腺苷受体的小分子拮抗剂 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2104931B1 (es) * | 1970-09-08 | 1975-01-10 | Ferlux | |
| CA2121391A1 (en) * | 1993-04-28 | 1994-10-29 | Atsuyuki Kojima | Indoloylguanidine derivatives |
| IL109570A0 (en) * | 1993-05-17 | 1994-08-26 | Fujisawa Pharmaceutical Co | Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
| US5852046A (en) | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
| EP0639573A1 (de) * | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
| DE4412334A1 (de) | 1994-04-11 | 1995-10-19 | Hoechst Ag | Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| CA2160600A1 (en) * | 1994-10-18 | 1996-04-19 | Masahumi Kitano | Indoloylguanidine derivatives |
| NZ314105A (en) | 1996-02-02 | 1997-12-19 | Sumitomo Pharma | Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring |
| JPH09291076A (ja) | 1996-04-24 | 1997-11-11 | Sumitomo Pharmaceut Co Ltd | 置換グアニジン誘導体およびその製法 |
| ZA9711102B (en) * | 1996-12-16 | 1998-08-13 | Yamanouchi Pharma Co Ltd | N-[(substituted 5-membered heteroaryl)carbonyl] guanidine derivative |
| KR100407903B1 (ko) * | 1998-02-27 | 2003-12-01 | 화이자 프로덕츠 인크. | 허혈 치료용 ｎ-[(치환된 5원 트리아자 이불포화고리)카르보닐] 구아니딘 유도체 |
-
1999
- 1999-02-05 KR KR10-2002-7017553A patent/KR100407903B1/ko not_active Expired - Fee Related
- 1999-02-05 TR TR2000/02480T patent/TR200002480T2/xx unknown
- 1999-02-05 JP JP2000533420A patent/JP2002504546A/ja active Pending
- 1999-02-05 SK SK1234-2000A patent/SK12342000A3/sk unknown
- 1999-02-05 PL PL99342444A patent/PL342444A1/xx not_active Application Discontinuation
- 1999-02-05 ES ES99901083T patent/ES2237080T3/es not_active Expired - Lifetime
- 1999-02-05 CA CA002321642A patent/CA2321642A1/en not_active Abandoned
- 1999-02-05 AU AU20706/99A patent/AU739403B2/en not_active Ceased
- 1999-02-05 KR KR10-2003-7009644A patent/KR20030078886A/ko not_active Ceased
- 1999-02-05 PT PT99901083T patent/PT1056729E/pt unknown
- 1999-02-05 ID IDW20001633A patent/ID25505A/id unknown
- 1999-02-05 KR KR10-2000-7009529A patent/KR100449600B1/ko not_active Expired - Fee Related
- 1999-02-05 EP EP04008203A patent/EP1454902A1/en not_active Withdrawn
- 1999-02-05 YU YU46200A patent/YU46200A/sh unknown
- 1999-02-05 EA EA200000789A patent/EA003603B1/ru not_active IP Right Cessation
- 1999-02-05 HU HU0204418A patent/HUP0204418A3/hu not_active Application Discontinuation
- 1999-02-05 CN CN99802628A patent/CN1289326A/zh active Pending
- 1999-02-05 SI SI9930743T patent/SI1056729T1/xx unknown
- 1999-02-05 HR HR20000550A patent/HRP20000550A2/hr not_active Application Discontinuation
- 1999-02-05 AT AT99901083T patent/ATE286034T1/de not_active IP Right Cessation
- 1999-02-05 NZ NZ504769A patent/NZ504769A/en unknown
- 1999-02-05 KR KR10-2003-7012300A patent/KR20030083004A/ko not_active Ceased
- 1999-02-05 EP EP99901083A patent/EP1056729B1/en not_active Expired - Lifetime
- 1999-02-05 IL IL13658899A patent/IL136588A0/xx unknown
- 1999-02-05 BR BR9908332-9A patent/BR9908332A/pt not_active IP Right Cessation
- 1999-02-05 DK DK99901083T patent/DK1056729T3/da active
- 1999-02-05 WO PCT/IB1999/000206 patent/WO1999043663A1/en not_active Ceased
- 1999-02-05 HR HR20010666A patent/HRP20010666A2/hr not_active Application Discontinuation
- 1999-02-05 DE DE69922930T patent/DE69922930T2/de not_active Expired - Fee Related
- 1999-02-05 US US09/367,731 patent/US6492401B1/en not_active Expired - Fee Related
- 1999-02-22 TW TW088102574A patent/TWI226329B/zh active
- 1999-02-22 GT GT199900022A patent/GT199900022A/es unknown
- 1999-02-23 PE PE1999000156A patent/PE20000334A1/es not_active Application Discontinuation
- 1999-02-24 TN TNTNSN99028A patent/TNSN99028A1/fr unknown
- 1999-02-24 DZ DZ990032A patent/DZ2729A1/xx active
- 1999-02-24 PA PA19998468401A patent/PA8468401A1/es unknown
- 1999-02-25 AP APAP/P/1999/001478A patent/AP9901478A0/en unknown
- 1999-02-25 AR ARP990100791A patent/AR015526A1/es unknown
- 1999-02-26 ZA ZA9901578A patent/ZA991578B/xx unknown
- 1999-03-01 CO CO99012526A patent/CO4980897A1/es unknown
-
2000
- 2000-06-27 IS IS5548A patent/IS5548A/is unknown
- 2000-08-18 OA OA1200000223A patent/OA11450A/en unknown
- 2000-08-22 NO NO20004192A patent/NO20004192D0/no not_active Application Discontinuation
- 2000-09-27 BG BG104803A patent/BG104803A/bg unknown
-
2002
- 2002-12-09 US US10/315,369 patent/US6974813B2/en not_active Expired - Fee Related
-
2004
- 2004-08-27 JP JP2004248129A patent/JP2005041879A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20000334A1 (es) | Compuestos para el tratamiento de la isquemia | |
| PE20000986A1 (es) | Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos | |
| PE20090116A1 (es) | Mezclas fungicidas que comprenden 1-metilpirazol-4-ilcarboxanilidas sustituidas | |
| PE20060459A1 (es) | DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA COMO INHIBIDORES DE LA ß-SECRETASA | |
| ES2509820T3 (es) | Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer | |
| PE20060691A1 (es) | Serinamidas sustituidas por benzoilo | |
| CA2213124A1 (en) | Benzoyl derivatives | |
| PE20061353A1 (es) | Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa | |
| CR11223A (es) | Compuestos de biciclolactama sustituida | |
| PE20060875A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina | |
| CO5150164A1 (es) | Derivados de pirazolopiridina | |
| AR107377A2 (es) | Compuestos derivados de tetrahidroquinolina | |
| TR199900782T2 (xx) | 1-benzil-3-(ikameli hetaril)-kayna�m�� pirazol t�revlerinin kullan�m�. | |
| PE20011001A1 (es) | Compuestos heterociclicos como inhibidores del intercambio de sodio/protones | |
| AR073586A1 (es) | Compuestos heterociclicos utiles para el tratamiento de vhc | |
| PE20080139A1 (es) | Compuestos de pirrolotriazina anilina como inhibidores de cinasa | |
| PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
| PE20070832A1 (es) | Derivados de piridazinona como inhibidores de la tirosina quinasa | |
| AR058719A1 (es) | Derivados de isoxazol-4-il-oxadiazol | |
| ATE540928T1 (de) | Isochinolinverbindungen und ihre medizinische verwendung | |
| BR9915128A (pt) | Pirimidin-4-enamina como fungicida | |
| NI201000049A (es) | Método para producir 2'-desoxi-5-azacitidina (decitabina) | |
| PE16299A1 (es) | Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoreceptores | |
| ES2531149T3 (es) | Derivados de 2-piridiniletilcarboxamida y su uso como fungicidas | |
| EA200601076A1 (ru) | Применение производных n-арилгидразина для борьбы с вредителями |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |